NCT00073749 - Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Lymphoma, B-Cell

Interventions

DRUG

Inotuzumab ozogamicin [CMC-544]

CMC-544, IV, dose escalation trial

Trial Locations (22)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

3000

Universitair Ziekenhuis Gasthuisberg, Leuven

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

35233

UAB CCC Clinical Studies Unit, Birmingham

University of Alabama at Birmingham Kirklin Clinic, Birmingham

35294

UAB Russell Ambulatory Pharmacy, Birmingham

University of Alabama at Birmingham, Birmingham

44195

The Cleveland Clinic Foundation, Cleveland

53105

Universitätsklinikum Bonn, Bonn

55131

Universitaetsmedizin der Johannes Gutenberg-Universitaet, Mainz

60611

Northwestern Medical Faculty Foundation, Chicago

Northwestern Memorial Hospital, Chicago

69495

Centre Hospitalier Lyon-Sud, Pierre-Bénite

75010

Hopital Saint Louis, Paris

81377

Medizinische Klinik und Poliklinik III, Klinikum der Universitat Muenchen-Grosshadern, München

Universitaet Muenchen Klinikum Grosshadern, München

77030-4009

M.D. Anderson Cancer Center, Houston

08025

Hospital de la Santa Creu I Sant Pau, Barcelona

08036

Hospital Clinic I Provincial, Barcelona

EC1A 7BE

St Bartholomew's Hospital, London